AbbVie Inc.
ABBVNYSEHealthcare● Active
$227.23
+$2.29(+1.02%)
Market Cap$401.5B
P/E Ratio—
52W High$244.81
52W Low$181.73
AbbVie Inc. (ABBV) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ABBV · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 29, 2026EPS Actual
$2.65
Est. $2.59 · +2.3%
Revenue
$15.00B
Est. $14.72B · +1.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 29, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 5-Quarter EPS Beat Streak
ABBV reports quarterly as a NYSE-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 30, 2026 | $3.79 | — | — | — | $16.78B | — |
| ▲ Q2 FY2026 | Apr 29, 2026 | $2.59 | $2.65 | +2.3% | $15.00B | $14.72B | +1.9% |
| ▲ Q1 FY2026 | Feb 4, 2026 | $2.65 | $2.71 | +2.3% | $16.62B | $16.41B | +1.3% |
| ▲ Q4 FY2025 | Oct 31, 2025 | $1.77 | $1.86 | +5.1% | $15.78B | $15.59B | +1.2% |
| ▲ Q3 FY2025 | Jul 31, 2025 | $2.88 | $2.97 | +3.1% | $15.42B | $15.03B | +2.6% |
| ▲ Q2 FY2025 | Apr 25, 2025 | $2.38 | $2.46 | +3.4% | $13.34B | $12.93B | +3.2% |
| ▼ Q1 FY2025 | Jan 31, 2025 | $2.98 | $2.16 | -27.5% | $15.10B | $14.83B | +1.8% |
| ▲ Q4 FY2024 | Oct 30, 2024 | $2.92 | $3.00 | +2.7% | $14.46B | $14.28B | +1.2% |
Q3 FY2026
Jul 30, 2026
EPS Actual
—
EPS Est.
$3.79
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 29, 2026Beat
EPS Actual
$2.65
EPS Est.
$2.59
EPS Surpr.
+2.3%
Revenue
$15.00B
Q1 FY2026
Feb 4, 2026Beat
EPS Actual
$2.71
EPS Est.
$2.65
EPS Surpr.
+2.3%
Revenue
$16.62B
Q4 FY2025
Oct 31, 2025Beat
EPS Actual
$1.86
EPS Est.
$1.77
EPS Surpr.
+5.1%
Revenue
$15.78B
Q3 FY2025
Jul 31, 2025Beat
EPS Actual
$2.97
EPS Est.
$2.88
EPS Surpr.
+3.1%
Revenue
$15.42B
Q2 FY2025
Apr 25, 2025Beat
EPS Actual
$2.46
EPS Est.
$2.38
EPS Surpr.
+3.4%
Revenue
$13.34B
Q1 FY2025
Jan 31, 2025Miss
EPS Actual
$2.16
EPS Est.
$2.98
EPS Surpr.
-27.5%
Revenue
$15.10B
Q4 FY2024
Oct 30, 2024Beat
EPS Actual
$3.00
EPS Est.
$2.92
EPS Surpr.
+2.7%
Revenue
$14.46B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $4.61 | $4.75 | $4.82 | 9 |
| Q3 FY2028 | $4.34 | $4.47 | $4.54 | 7 |
| Q2 FY2028 | $4.35 | $4.48 | $4.55 | 6 |
| Q1 FY2028 | $3.32 | $3.42 | $3.47 | 6 |
| Q4 FY2027 | $4.29 | $4.42 | $4.49 | 5 |
| Q3 FY2027 | $4.12 | $4.24 | $4.31 | 5 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $20.2B | $20.6B | $20.9B | 6 |
| Q3 FY2028 | $19.7B | $20.2B | $20.4B | 5 |
| Q2 FY2028 | $19.2B | $19.6B | $19.8B | 5 |
| Q1 FY2028 | $17.3B | $17.7B | $17.9B | 6 |
| Q4 FY2027 | $19.0B | $19.4B | $19.6B | 6 |
| Q3 FY2027 | $18.2B | $18.6B | $18.8B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 29, 2026 | +2.3% | $197.69 | $203.89 | +3.14% |
| ▲ Q1 FY2026 | Feb 4, 2026 | +2.3% | $225.66 | $217.11 | -3.79% |
| ▲ Q4 FY2025 | Oct 31, 2025 | +5.1% | $228.20 | $218.04 | -4.45% |
| ▲ Q3 FY2025 | Jul 31, 2025 | +3.1% | $189.31 | $189.02 | -0.15% |
| ▲ Q2 FY2025 | Apr 25, 2025 | +3.4% | $180.37 | $186.06 | +3.15% |
| ▼ Q1 FY2025 | Jan 31, 2025 | -27.5% | $175.65 | $183.90 | +4.70% |
| ▲ Q4 FY2024 | Oct 30, 2024 | +2.7% | $189.45 | $201.50 | +6.36% |
| ▲ Q3 FY2024 | Jul 25, 2024 | +3.1% | $176.21 | $182.17 | +3.38% |
Q2 FY2026+3.14%
Report Date
Apr 29, 2026
EPS Beat/Miss
+2.3%
Price Before
$197.69
Price After
$203.89
Q1 FY2026-3.79%
Report Date
Feb 4, 2026
EPS Beat/Miss
+2.3%
Price Before
$225.66
Price After
$217.11
Q4 FY2025-4.45%
Report Date
Oct 31, 2025
EPS Beat/Miss
+5.1%
Price Before
$228.20
Price After
$218.04
Q3 FY2025-0.15%
Report Date
Jul 31, 2025
EPS Beat/Miss
+3.1%
Price Before
$189.31
Price After
$189.02
Q2 FY2025+3.15%
Report Date
Apr 25, 2025
EPS Beat/Miss
+3.4%
Price Before
$180.37
Price After
$186.06
Q1 FY2025+4.70%
Report Date
Jan 31, 2025
EPS Beat/Miss
-27.5%
Price Before
$175.65
Price After
$183.90
Q4 FY2024+6.36%
Report Date
Oct 30, 2024
EPS Beat/Miss
+2.7%
Price Before
$189.45
Price After
$201.50
Q3 FY2024+3.38%
Report Date
Jul 25, 2024
EPS Beat/Miss
+3.1%
Price Before
$176.21
Price After
$182.17
Avg Beat Reaction+1.09%
Avg Miss Reaction+4.70%
Beat Rate7 / 8 quarters
Largest Move+6.36% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ABBV ends December
AbbVie Inc. (ABBV) most recently reported earnings on April 29, 2026 for Q2 FY2026, posting EPS of $2.65 — beating the analyst consensus of $2.59 by +2.3%. ABBV has beaten EPS estimates for 5 consecutive quarters. The next ABBV earnings date is expected around September 1, 2026.
Each quarter, investors track ABBV earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ABBV revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ABBV's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ABBV earnings · 5 questionsAbbVie Inc.'s next earnings report is expected around September 1, 2026. ABBV typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ABBV historically reports after market close (AMC).
ABBV earnings datewhen is ABBV earningsABBV next earnings datewhen does ABBV report earningsABBV earnings calendar
▸ Source: FMP · AbbVie Inc. SEC filings · US GAAP · AbbVie Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026